

Designation	447-52D (also designated as 447)
Product	human monoclonal antibody to V3 of HIV-1 gp120 epitope KSIHIGPGRAF
Product no.	AB014
Lot no.	xxx
Shelf life	unopened at least until: mm yyyy
Volume	xxx µl
Concentration	x.xx mg/ml
Method of analysis	OD 280 nm
Isotype	IgG3 (λ)
Host cell	hetero-hybridoma
Purification	protein A affinity chromatography
Product buffer	PBS – sterile, no preservatives <i>Handling under non-sterile conditions can cause contamination leading to protein degradation!</i>
Formulation	liquid
Storage conditions	+ 2-8°C

Note: For use as research reagent only

The permission to use the cell line for the manufacture of this product was obtained from New York University School of Medicine, 650 First Avenue, 6 Floor, New York, NY 10016, USA. Special acknowledgement is given to Dr. Susan Zolla-Pazner and Dr. Mirosław K. Gorny, both New York University School of Medicine, who established and characterized this antibody.

See page 2 for more detailed information on antibody 447-52D

WARRANTY AND LIMITATION OF REMEDY

Polymun Scientific Immunbiologische Forschung GmbH makes no warranty of any kind, expressed or implied, including, but not limited to, the warranties of fitness for a particular purpose and merchantability, which extends beyond the description of the chemicals on the face hereof, except that the material will meet our specifications at the time of delivery. Buyer's exclusive remedy and Polymun Scientific Immunbiologische Forschung GmbH's sole liability hereunder shall be limited to refund of the purchase price of, or at Polymun Scientific Immunbiologische Forschung GmbH's option the replacement of, all material that does not meet our specifications. Polymun Scientific Immunbiologische Forschung GmbH shall not be liable otherwise or for incidental or consequential damages, including, but not limited to, the costs of handling. Said refund or replacement is conditioned on Buyer giving written notice to Polymun Scientific Immunbiologische Forschung GmbH within thirty (30) days after arrival of the material at its destination. Failure of Buyer to give said notice within said thirty (30) days shall constitute a waiver by Buyer of all claims hereunder with respect to said material.

Polymun Scientific Immunbiologische Forschung GmbH, September 15th 2010

Human monoclonal antibody (mAb) 447-52D was originally derived from an individual infected with clade B HIV-1 and was generated using a cellular technique (1). The antibody neutralizes laboratory strains (1, 2), clinical isolates (3) and pseudotyped viruses (4) in the range between 30% and 50% of HIV-1 in panels of tested viruses from clade A, B, F and H (4, 5). It preferentially neutralizes viruses that contain the GPGR motif in the V3 crown, with limited capacity against those with the GPGQ motif (4). Its neutralization potency against pseudoviruses with an R to Q mutation in the crown motif is decreased ~700-fold (6). 447-52D is extensively cross-reactive, especially with V3 peptides representing sequences of clade B viruses (7). The X-ray structure of this antibody complexed with a V3 peptide explained that it depends on reactivity with the conserved GPxR sequence at the tip of the loop and on interactions with the main chain of the surrounding variable sequence (8, 9). This mAb binds to virus-infected cells (10), and reacts with intact virions (11). Use in ELISA at 1 µg/ml.

1. Gorny et al., J Virol., 1992, 66:7538-7542.
2. Gorny et al., J Immunol., 1993, 150:635-643.
3. Conley et al., J Virol., 1994, 68:6994-7000.
4. Hioe et al., PLoS ONE, 2010, 5:e10254.
5. Binley et al., J. Virol. 2004, 78:13232-13252.
6. Krachmarov et al., J Virol., 2006, 80:7127-7135.
7. Gorny et al., J Immunol., 1997, 159:5114-5122.
8. Stanfield et al., Structure, 2004, 12:193-204.
9. Burke et al., Structure, 2009, 17:1538-1546.
10. Zolla-Pazner et al., J Virol., 1995, 69:3807-3815.
11. Nyambi et al., J Virol., 1998, 72:9384-9391.